Which controlled substances do not need to be reported when administered in a narcotic treatment program?

In the context of narcotic treatment programs, there are specific regulations concerning the reporting of controlled substances. Controlled substances that are administered within a narcotic treatment program are exempt from the reporting requirements typically associated with the dispensing of such medications. This is because these substances are being used for the specific purpose of treating opioid dependence and are part of a structured treatment plan regulated by the Substance Abuse and Mental Health Services Administration (SAMHSA).

A narcotic treatment program is designed to provide comprehensive care to individuals battling opioid addiction, which includes the administration of medications such as methadone or buprenorphine. The focus is on therapeutic outcomes rather than simply tracking the dispensing of medications. This exemption is rooted in the understanding that the treatment process needs to prioritize the recovery and well-being of the patients, not complicate their care with additional administrative burdens related to reporting.

Therefore, the correct choice reflects the recognition that controlled substances administered in this specific therapeutic setting are treated differently to support effective addiction treatment.